NeurologyLive Friday 5 — July 31, 2020

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending July 31, 2020.

Welcome to NeurologyLive's Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: AAIC 2020: Nilotinib Has Safe and Tolerable Profile in Alzheimer Disease

Results presented virtually by Raymond Scott Turner, MD, PhD, support a larger, multi-center, phase 3 study to determine the safety and efficacy of nilotinib in patients with Alzheimer disease.

READ MORE

2: Insights: Spectrum of SMA Phenotypes at Presentation

Tim Hagenacker, MD, describes spinal muscular atrophy as a very broad clinical spectrum disease, highlighting the various ways it can present in patients.

WATCH NOW

3: AAIC 2020: Influenza, Pneumonia Vaccination May Reduce Alzheimer Disease Risk

A trio of studies suggest that consistently vaccinations for influenza and pneumonia may reduce the incidence of Alzheimer later in life, as well as mortality for older adults.

READ MORE

4: Podcast: Trends in the Alzheimer Clinical Pipeline

"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Jeffrey Cummings, MD, ScD, who discusses a recent review he and colleagues did of the trends in the Alzheimer Disease pipeline and what he expects for the future of the disease's care.

LISTEN NOW

5: Ped-MSSS May Serve as Alternative to EDSS in Pediatric-Onset MS

The findings indicate that the use of a MS severity score (Ped-MSSS) model may provide an alternative to EDSS scoring, which has been shown to be lower in pediatric disease, in clinical assessment of disease severity and disability accrual.

READ MORE

Related Videos
View All
© 2023 MJH Life Sciences

All rights reserved.